An advisory panel of experts to the U.S. drug regulator will conduct meetings this month to review data on Pfizer Inc’s coronavirus vaccines in young children, and whether to clear booster doses of Moderna and Johnson & Johnson’s vaccines.
As health authorities seek out to mitigate a potential increase of cases this fall, with schools already open nationwide, this announcement has been made by the U.S. Food and Drug Administration.
To discuss a booster dose of Moderna Vaccine and Johnson & Johnson on Oct. 15 the FDA’s vaccines are Related Biological Products Advisory Committee (VRBPAC) panel will hold a meeting on Oct. 14.
The global business leaders will talk on a vast range of topics starting from sustainability and the geo-political outlook to emerging business trends. VRBPAC will discuss authorizing Pfizer Inc’s coronavirus vaccine for children aged between five through 11 on Oct. 26, said the FDA.
According to data from the Centers for Disease Control and Prevention, around 4 million Americans had received a booster dose as of Thursday.
The panel will also review data on receiving a booster dose of a different vaccine than the one used in the original vaccine series, called “mix and match” boosters.
According to reports of Reuters, the disease experts were considering the need for booster shots of the Pfizer/BioNTech or Moderna’s mRNA-based vaccines for Americans who received the J&J one-dose vaccine due to the prevalence of the Delta variant of the COVID-19 virus.
Separately, the FDA does not plan to extend the shelf life of hundreds of thousands of J&J vaccine doses beyond the current recommendation of six months from the manufacturer, NBC News reported.
